دورية أكاديمية
أعرض في EDS

Impact of BRCA1/2 Mutations on the Efficacy of Secondary Cytoreductive Surgery.

التفاصيل البيبلوغرافية
العنوان: Impact of BRCA1/2 Mutations on the Efficacy of Secondary Cytoreductive Surgery.
المؤلفون: Estati FL; Department of Medical Oncology, A.C. Camargo Cancer Center, São Paulo, SP, Brazil., Pirolli R; Department of Medical Oncology, A.C. Camargo Cancer Center, São Paulo, SP, Brazil., de Alencar VTL; Department of Medical Oncology, A.C. Camargo Cancer Center, São Paulo, SP, Brazil., Ribeiro ARG; Department of Medical Oncology, A.C. Camargo Cancer Center, São Paulo, SP, Brazil., Formiga MN; Department of Medical Oncology, A.C. Camargo Cancer Center, São Paulo, SP, Brazil.; Department of Oncogenetics, A.C. Camargo Cancer Center, São Paulo, SP, Brazil., Torrezan GT; Genomics and Molecular Biology Group, A.C. Camargo Cancer Center, São Paulo, SP, Brazil., Carraro DM; Genomics and Molecular Biology Group, A.C. Camargo Cancer Center, São Paulo, SP, Brazil., Guimarães APG; Department of Medical Oncology, A.C. Camargo Cancer Center, São Paulo, SP, Brazil., Baiocchi G; Department of Gynecology Oncology, A.C. Camargo Cancer Center, São Paulo, SP, Brazil., da Costa AABA; Department of Medical Oncology, A.C. Camargo Cancer Center, São Paulo, SP, Brazil. alexandre.costa@accamargo.org.br.
المصدر: Annals of surgical oncology [Ann Surg Oncol] 2021 Jul; Vol. 28 (7), pp. 3637-3645. Date of Electronic Publication: 2020 Nov 21.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 9420840 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-4681 (Electronic) Linking ISSN: 10689265 NLM ISO Abbreviation: Ann Surg Oncol Subsets: MEDLINE
أسماء مطبوعة: Publication: 2005- : New York, NY : Springer
Original Publication: New York, NY : Raven Press, c1994-
مواضيع طبية MeSH: Cytoreduction Surgical Procedures* , Ovarian Neoplasms*/drug therapy , Ovarian Neoplasms*/genetics , Ovarian Neoplasms*/surgery, BRCA1 Protein/*genetics , BRCA2 Protein/*genetics, Carcinoma, Ovarian Epithelial ; Female ; Germ-Line Mutation ; Humans ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/surgery
مستخلص: Background: Phase III trials evaluating the role of secondary cytoreductive surgery (SCS) in recurrent ovarian cancer have pointed to the importance of patient selection. Two studies showed conflicting results regarding the benefit of SCS in BRCA1/2 mutation carriers. Our aim was to evaluate the impact of SCS on recurrent ovarian cancer according to BRCA1/2 status.
Methods: All patients with ovarian carcinoma with platinum-sensitive recurrent disease and tested for BRCA1/2 germline mutations were included. Cox regression and log rank test were used to evaluate the impact of SCS on progression-free survival (PFS) and the influence of BRCA1/2 mutations on the effect of SCS.
Results: 127 patients were included, 45.6% were treated with SCS and chemotherapy and 54.3% treated with chemotherapy only. Patients treated with SCS were younger, presented better performance status, had lower CA125, and had a longer platinum-free interval. In multivariate analysis SCS was associated with longer PFS (HR 0.42, 95% CI 0.25-0.72, p = 0.002). BRCA1/2 mutations were found in 35 patients (27.5%), and 11.8% of patients were treated with PARP inhibitors. Although not statistically significant, both BRCA1/2 wild type patients (PFS: 21.6 vs 18.4 months; p = 0.114) and BRCA1/2 mutation carriers (PFS: 23.1 vs 18.2 months, p = 0.193) appeared to derive benefit from SCS.
Discussion: The present study suggests a benefit of SCS irrespective of BRCA1/2 status among patients mostly not treated with PARP inhibitor. Further data on post hoc analysis from the phase III trials are warranted to confirm whether BRCA1/2 mutated patients should be selected for SCS.
References: Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. https://doi.org/10.3322/caac.21590. (PMID: 10.3322/caac.2159031912902)
Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018. https://doi.org/10.3322/caac.21456. (PMID: 10.3322/caac.21456305484826621554)
Raja FA, Counsell N, Colombo N, et al. Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data. Ann Oncol. 2013;24(12):3028–3034. https://doi.org/10.1093/annonc/mdt406. (PMID: 10.1093/annonc/mdt40624190964)
Aghajanian C, Blank S V., Goff BA, et al. OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039–2045. https://doi.org/10.1200/jco.2012.42.0505. (PMID: 10.1200/JCO.2012.42.0505225292653646321)
Coleman RL, Brady MF, Herzog TJ, et al. Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(6):779–791. https://doi.org/10.1016/s1470-2045(17)30279-6. (PMID: 10.1016/S1470-2045(17)30279-6284384735715461)
Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154–2164. https://doi.org/10.1056/nejmoa1611310. (PMID: 10.1056/NEJMoa161131027717299)
Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014. https://doi.org/10.1016/s1470-2045(14)70228-1. (PMID: 10.1016/S1470-2045(14)70228-124882434)
Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949–1961. https://doi.org/10.1016/s0140-6736(17)32440-6. (PMID: 10.1016/S0140-6736(17)32440-6289163675901715)
Du Bois A, Vergote I, Ferron G, et al. Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20. J Clin Oncol. 2017;35(15_suppl):5501. https://doi.org/10.1200/jco.2017.35.15_suppl.5501.
Coleman RL, Spirtos NM, Enserro D, et al. Secondary surgical cytoreduction for recurrent ovarian cancer. N Engl J Med. 2019;381(20):1929–1939. https://doi.org/10.1056/nejmoa1902626. (PMID: 10.1056/NEJMoa1902626317221536941470)
Bois A, Sehouli J, Ferron G, et al. Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20. J Clin Oncol. 2020;38:6000. https://doi.org/10.1200/jco.2020.38.15_suppl.6000. (PMID: 10.1200/JCO.2020.38.15_suppl.6000)
Zang R, Zhu J, Shi T, et al. A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2. J Clin Oncol. 2020;38(15_suppl):6001. https://doi.org/10.1200/jco.2020.38.15_suppl.6001.
13. Bell D, Berchuck A, Birrer M, et al. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-615. https://doi.org/10.1038/nature10166. (PMID: 10.1038/nature10166)
Cotrim DP, Ribeiro ARG, Paixão D, et al. Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil. BMC Cancer. 2019;19(1):1–9. https://doi.org/10.1186/s12885-018-5235-3. (PMID: 10.1186/s12885-018-5235-3)
Norquist BM, Harrell MI, Brady MF, et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2016;2(4):482–490. https://doi.org/10.1001/jamaoncol.2015.5495. (PMID: 10.1001/jamaoncol.2015.5495267207284845939)
Harter P, Hauke J, Heitz F, et al. Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). PLoS One. 2017;12(10):1–12. https://doi.org/10.1371/journal.pone.0186043. (PMID: 10.1371/journal.pone.0186043)
Maistro S, Teixeira N, Encinas G, et al. Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil. BMC Cancer. 2016;16(1):1–8. https://doi.org/10.1186/s12885-016-2966-x. (PMID: 10.1186/s12885-016-2966-x)
Bolton KL, Chenevix-Trench G, Goh C, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA. 2012;307(4):382–390. https://doi.org/10.1001/jama.2012.20. (PMID: 10.1001/jama.2012.20222746853727895)
Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group. J Clin Oncol. 2012;30(21):2654–2663. https://doi.org/10.1200/jco.2011.39.8545. (PMID: 10.1200/JCO.2011.39.8545227118573413277)
Lavie O, Chetrit A, Novikov I, Sadetzki S. Fifteen-year survival of invasive epithelial ovarian cancer in women with BRCA1/2 mutations—the National Israeli Study of Ovarian Cancer. Gynecol Oncol. 2019;153(2):320–325. https://doi.org/10.1016/j.ygyno.2019.02.022. (PMID: 10.1016/j.ygyno.2019.02.02230872026)
Marchetti C, De Leo R, Musella A, et al. BRCA Mutation status to personalize management of recurrent ovarian cancer: a multicenter study. Ann Surg Oncol. 2018;25(12):3701–3708. https://doi.org/10.1245/s10434-018-6700-6. (PMID: 10.1245/s10434-018-6700-630128899)
Marchetti C, Rosati A, Scaletta G, et al. Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study. Gynecol Oncol. 2019;155(3):400–405. https://doi.org/10.1016/j.ygyno.2019.09.020. (PMID: 10.1016/j.ygyno.2019.09.02031606285)
Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495-2505. https://doi.org/10.1056/nejmoa1810858. (PMID: 10.1056/NEJMoa181085830345884)
Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416–2428. https://doi.org/10.1056/nejmoa1911361. (PMID: 10.1056/NEJMoa191136131851799)
González-Martín A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391–2402. https://doi.org/10.1056/nejmoa1910962. (PMID: 10.1056/NEJMoa191096231562799)
Hyman DM, Long KC, Tanner EJ, et al. Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma. Gynecol Oncol. 2012;126(2):224–228. https://doi.org/10.1016/j.ygyno.2012.05.001. (PMID: 10.1016/j.ygyno.2012.05.001225797903909698)
Petrillo M, Marchetti C, De Leo R, et al. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study. Am J Obstet Gynecol. 2017;217(3):334.e1–334.e9. https://doi.org/10.1016/j.ajog.2017.05.036. (PMID: 10.1016/j.ajog.2017.05.036)
Liu Z, Beach JA, Agadjanian H, et al. Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation. Obstet Gynecol Surv. 2016;71(5):285–286. https://doi.org/10.1097/ogx.0000000000000320. (PMID: 10.1097/OGX.0000000000000320)
المشرفين على المادة: 0 (BRCA1 Protein)
0 (BRCA1 protein, human)
0 (BRCA2 Protein)
0 (BRCA2 protein, human)
تواريخ الأحداث: Date Created: 20201122 Date Completed: 20210609 Latest Revision: 20220531
رمز التحديث: 20231215
DOI: 10.1245/s10434-020-09366-w
PMID: 33221980
قاعدة البيانات: MEDLINE
الوصف
تدمد:1534-4681
DOI:10.1245/s10434-020-09366-w